News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

New glioblastoma clinical trial: mTOR inhibitor ABI-009

Al's Comment:

 This is a new trial for newly diagnosed GBM or recurrent high grade glioma in adults (age 18+).


Posted on: 08/24/2018

New glioblastoma clinical trial: mTOR inhibitor ABI-009

 

Aadi Bioscience, Inc. in collaboration with John Wayne Cancer Institute, is conducting a clinical research study for patients with recurrent high-grade glioma or newly diagnosed glioblastoma.

 

 

The main goal of this research is to investigate the efficacy of the mTOR inhibitor ABI-009 in combination with existing therapies in patients with recurrent high-grade glioma or newly diagnosed glioblastoma.   The experimental drug is a novel nanoparticle albumin-bound rapamycin (nab-rapamycin).

 

 

Study Design

Prospective
Multi-cohort
Phase II, open label
Non-randomized
Single site

 

 

There are three (3) study periods:

 
1.A Screening Period to determine eligibility, which lasts approximately 3 weeks
 
2.A Treatment period, which lasts approximately 6 months for patients with recurrent high-grade glioma and up to 12 months for patients with newly diagnosed glioblastoma, where subjects receive weekly ABI-009 for 2 out of every 3 weeks or 3 out of every 4 weeks by IV infusion over 30 minutes

 

3.A Follow-up period to assess safety, survival and anticancer therapy, with phone call follow-up occurring every 12 weeks

Key Eligibility Criteria

Patients must have:

Patients must have:
≥18 years old
KPS ≥ 70%
No pregnancy or breastfeeding, contraception required
For patients with recurrent high-grade glioma:
All patients must have histologic evidence of high grade glioma (World Health Organization [WHO] grade 3 or grade 4) and radiographic evidence of recurrence or disease progression
No prior mTOR inhibitors or BEV or other anti-angiogenic agents, no prior treatment with respective agent for recurrent disease in combo cohorts
For patients with newly diagnosed glioblastoma:
Patients must have had surgery and have a measurable post-contrast lesion after surgery detected by MRI.
No prior mTOR inhibitors and no prior local or systemic therapy for GBM.


You may reference additional study information on ClinicalTrials.gov at:
https://www.clinicaltrials.gov/ct2/show/NCT03463265

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740